Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9612MR)

This product GTTS-WQ9612MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9612MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15915MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8998MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ13395MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ10466MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ8117MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ1262MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ2380MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ9341MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW